news

Greenberg Traurig has represented Japan’s Ono Pharmaceutical Co on its $2.4 billion acquisition of  U.S.-based cancer drugmaker Deciphera, which was advised by Goodwin Procter.

According to Reuters, the deal will help Ono expand its oncology portfolio and presence in the United States and Europe.

Deciphera's oral drug Qinlock, which treats a type of gastrointestinal cancer, received the U.S. Food and Drug Administration's full approval in 2020. The company also plans to seek a nod for vimseltinib, its experimental medicine to treat tenosynovial giant cell tumour, a type of tumour found in some joints, Reuters added.

The Greenberg Traurig team was co-led by shareholders Chia-Feng Lu and Michael D. Helsel, while the Goodwin team was helmed by global M&A head Stuart Cable and partners Richard Hoffman, Lisa Haddad, and James Ding.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

PAG GC to join MoFo Tokyo as partner

Morrison & Foerster is set to boost its private equity and M&A practices in Asia with the hire of veteran corporate lawyer Gregory Salathé as a partner in Tokyo. Salathé will join the firm in September from investment manager PAG, where he is currently a partner and group general counsel.

A&G, WongP acting on OCBC’s $1 bln buyout offer for Great Eastern

Singapore Big Four law firm WongPartnership is advising insurer Great Eastern Holdings in relation to a S$1.4 billion ($1 billion) buyout offer from its top shareholder, Oversea-Chinese Banking Corporation (OCBC), which is being represented by Allen & Gledhill.

NO&T, MHM advising on $1.4 bln Kirin-Fancl deal

Nagashima Ohno & Tsunematsu is advising Japan’s Kirin Holdings on its 220.7 billion yen ($1.4 billion) offer to acquire the rest of skincare brand Fancl Corp, which is being represented by Uryu & Itoga.